HC Wainwright & Co. Maintains Buy Rating for Greenwich LifeSciences: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has maintained its Buy rating for Greenwich LifeSciences (NASDAQ:GLSI) but lowered its price target from $38.00 to $36.00. Shares of GLSI have risen 4.98% in the last 24 hours to $11.80. The new price target suggests a potential increase of 205.08% from the current price. Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing immunotherapies for breast cancer recurrences.
February 20, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains Buy rating on Greenwich LifeSciences with a lowered price target from $38.00 to $36.00, indicating a significant upside potential from the current price.
The maintenance of a Buy rating by a reputable analyst firm like HC Wainwright & Co. generally signals confidence in the company's future performance, despite the slight reduction in the price target. The significant potential upside indicated by the new price target could generate investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100